ACRS
Aclaris TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The best support in the packet is still company-sourced: ATI-052 Phase 1a data were described as exceeding target profile with potential dosing up to every three months, and management kept multiple 2026 readouts on track while pointing to runway through 2028 [#SEC-8K-2026-05-07].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +9.3.
What can break
Bosakitug Phase 2 atopic dermatitis results are another high-impact binary event, and a miss would weaken the broader anti-TSLP thesis.
Momentum
88
Value
41
Sentiment
26
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.20 · Bull $7.50 · Bear $2.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $10.45
Why
Momentum88 · Δ7d +9.3
Value41 · Δ7d -0.1
Sentiment26 · Δ7d -3.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
88
26% active weight
Current posture
7d trendImproving
Δ7d
+9.3
Δ21d
+9.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
26
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.5
Δ21d
-11.7
Why this grade
Composite grade D. Momentum 87.6 / Value 41.1 / Sentiment 25.9
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$793.29M
Beta
0.87
Shares Out
139.66M
P/E (TTM) · Derived
-10.7
P/S (TTM)
18.24
P/FCF (TTM) · Derived
-13.55
Rev YoY
+37.2%
EPS YoY
+24.9%
Gross Margin
+9.7%
Op Margin
-973.9%
Net Debt
-$88.64M
Current Ratio
4.03
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology